Tracking tumor DNA over time in neuroblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational program that enrolls newly diagnosed and relapsed/refractory neuroblastoma patients and collects serial biospecimens during routine clinical care. Plasma samples are obtained at baseline, during treatment, after surgery when applicable, during post-treatment surveillance, and at suspected relapse or progression, with bone marrow or CSF analyzed in selected cases. Molecular testing uses both tumor-informed personalized MRD assays and fixed-panel approaches to characterize baseline genomic alterations and dynamic ctDNA changes. Results will be correlated with imaging, marrow, serum markers, and clinical outcomes to determine whether ctDNA/MRD improves response assessment, molecular remission evaluation, and relapse surveillance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically or clinically confirmed neuroblastoma according to institutional or protocol-defined diagnostic criteria.

Newly diagnosed, relapsed, refractory, or progressive neuroblastoma eligible for serial biospecimen collection during routine clinical care.

Availability of peripheral blood samples for ctDNA/MRD analysis at baseline and/or longitudinal follow-up time points.

Availability of clinical data required for molecular-clinical correlation analyses, including response and outcome assessment.

Availability of tumor tissue and matched control samples for tumor-informed assay development, if applicable and feasible.

Written informed consent from a parent or legal guardian, and assent from the participant when applicable.

Exclusion Criteria:

* Inability to provide protocol-required blood samples for ctDNA/MRD testing. Insufficient clinical information for protocol-defined response or outcome analyses.

Poor-quality or insufficient biospecimens that preclude molecular analysis, when molecular testing is a required component of the study dataset.

Any condition that, in the opinion of the investigator, would make study participation inappropriate.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Yizhuo Zhang, Doctor of Haematology
• Email: zhangyzh@sysucc.org.cn
• Phone: +86 18819241079

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neuroblastoma patients' genomic and biological profile study

  This multicenter, prospective study tests profiles from blood, tumor tissue, and bone marrow to understand neuroblastoma in diagnosed, relapsed, or refractory patients.

  Recruiting at 35 sites Istituto Giannina Gaslini · Ancona and 34 other locations · NCT07881172

• CIML-NK Cells to Treat Neuroblastoma in Relapsed or Refractory Patients

  We’re testing whether donor-derived cytokine-induced memory-like NK cells can be safely given with dinutuximab to kids and young adults whose neuroblastoma has come back or not responded to treatment.

  Recruiting Phase 2 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07635056

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Anti-GD2-800CW imaging to highlight neuroblastoma during surgery

  This trial will test whether a fluorescent antibody called anti-GD2-800CW can safely help surgeons see and remove neuroblastoma in children ages 1 to 18.

  Recruiting Phase 1/2 Princess Maxima Center for Pediatric Oncology · Utrecht · NCT07399821

• B7-H3 CAR T cells for relapsed or refractory solid tumors in children and young adults

  This study tests a new B7-H3 CAR T cell therapy to see if it is safe and can help kids and young adults whose solid tumors have come back or stopped responding to standard treatments.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07358260

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.